# Verixa Investor Event Deep Research — New Events Beyond Current Tracker

## Priority ranking table

| Rank | Event / program | Window & location | ROI tier | Recommended Verixa posture | Why it fills a gap |
|---:|---|---|---|---|---|
| 1 | HLTH USA Startup Pitch | Nov. 15–18, 2026; Venetian Expo, Las Vegas | HIGH | Apply for startup pitch after patent/compliance clearance; use 1:1s and Digital Health Awards if public pitch is not cleared | Dedicated seed/growth startup pitch in front of healthcare investors, strategics, and operators, with 12,250+ attendees and judges historically including a16z, GV, Khosla, General Catalyst, Flare, Cigna Ventures, Cleveland Clinic, and Oak HC/FT ([HLTH USA](https://hlth.com/events/usa/), [HLTH Startup Pitch](https://hlth.com/events/usa/agenda/startup-pitch/)). |
| 2 | RESI JPM 2027 / RESI San Francisco | Jan. 11–12, 2027 in San Francisco, with virtual partnering Jan. 13, 18–19 | HIGH | Partnering-first; private 1:1 meetings pre-clearance; public pitch only after dual-gate | Fills the missing Life Science Nation SF/JPM-week investor forum gap; prior RESI JPM drew over 1,000 attendees and 500+ early-stage life-science investors, and the 2026–27 RESI calendar lists RESI JPM 2027 as San Francisco plus virtual partnering ([RESI JPM](https://www.resiconference.com/resi-jpm/), [RESI Europe program guide](https://www.lifesciencenation.com/wp-content/uploads/Digital-RESI-Europe-2026-Program-Guide_v3.5.pdf)). |
| 3 | Slush 2026 | Nov. 18–19, 2026; Helsinki | HIGH | Seed fundraising sprint framed as regulated AI/deeptech SaaS; book investor meetings, office hours, and side events | Adds a non-healthcare-specific but very high-density seed investor market: Slush says 2026 will host 5,800 startups and 3,300 investors, with investor day, a meeting tool, and 20,000+ meetings ([Slush](https://slush.org), [Slush FAQ](https://slush.org/faq)). |
| 4 | LSX World Congress Europe 2027 | Apr. 6 pre-day forums; Apr. 7–8, 2027 main days; Lyon, France | HIGH | 1:1 partnering and investor pitch; target digital health, pharma CVC, and life-science funds | Directly fills a European life-science fundraising gap and is explicitly Seed–Series B friendly for biotech, medtech, diagnostics, and digital health companies ([LSX World Congress](https://informaconnect.com/lsx-world-congress/)). |
| 5 | India Pharma Conference | Next cycle TBA; 2026 edition was Apr. 13–14, 2026 at FICCI Federation House, New Delhi | HIGH | Strategic investor / pharma CVC / policy-channel networking; not a generic pitch event | Best India pharma-specific strategic platform found outside TiE, BTS, and BioAsia: organized by Department of Pharmaceuticals with FICCI and IPA, with a 2026 financing plenary on VC, PE, blended finance, PPPs, and pharma innovation funding ([PIB announcement](https://www.pib.gov.in/PressReleasePage.aspx?PRID=2246902&reg=6&lang=1), [PIB conclusion note](https://www.pib.gov.in/PressReleasePage.aspx?PRID=2251887&reg=1&lang=1)). |
| 6 | C-CAMP National Bio Entrepreneurship Competition (NBEC) | 2026 application cycle closed June 15, 2026; next cycle likely 2027 | HIGH | Apply next cycle; use as India life-science validation and investor-access credential | Best India early-stage bio/life-sciences pitch route found, with healthcare, digital health, AI/ML, diagnostics, and biotech scope and up to INR 20 crore in prize money plus investment opportunities for startups ([IIMA Ventures / C-CAMP post](https://www.linkedin.com/posts/iimaventures_iimaventures-ccamp-nbec-activity-7462441875308892160-huS0), [IndiaBioscience post](https://x.com/IndiaBioscience/status/2059185766283243568)). |
| 7 | Digital Healthcare Innovation Summit (DHIS) East + Cooley Capital Call | Apr. 27–28, 2026 Boston; 2027 cycle TBA | HIGH | Apply for Capital Call when 2027 opens; private materials until public clearance | Strong seed–Series A digital health investor stage: 2026 Capital Call was designed for seed-to-Series A companies, included AI in healthcare and pharma IT/services, and offered live pitching to VCs at DHIS ([Cooley Capital Call](https://www.cooley.com/events/2026/2026-04-27-call-for-applications-cooley-capital-call-at-digital-healthcare-innovation-summit), [DHIS East](https://dhis.net/east)). |
| 8 | Rock Health Summit | Oct. 14, 2026; San Francisco | HIGH | Attend and schedule 1:1s; avoid relying on formal pitch stage | Rock Health’s signature digital health gathering convenes entrepreneurs, investors, health systems, payers, and consultants, with past speaker/investor relevance including a16z and Lux Capital leaders ([Rock Health Summit](https://www.rockhealthsummit.com)). |
| 9 | BIO Investment & Growth Summit (BIO BIG), replacing 2026 BIO Investor Forum focus | Feb. 16–18, 2027; Miami, FL | MEDIUM-HIGH | Partnering and company-presentation route; use pharma investor network, not pure SaaS pitch | BIO says 2027 BIG Summit brings select private/newly public biotech companies with investment banking community for sessions, company presentations, BIO Partnering, and networking; BIO’s FAQ says 2026 investor engagement was focused through BIG rather than separate BIO CEO & Investor Conference and BIO Investor Forum ([BIO Events](https://www.bio.org/events), [BIO BIG FAQ](https://bigs.bio.org/faqs-1/big-summit-same-ceo-investor-conference-bio-investor-forum)). |
| 10 | LSX Investival Showcase USA | Mar. 9–10, 2027; Miami | MEDIUM-HIGH | Seed–Series B life-sciences investor meetings; test US investor appetite | LSX USA says it connects companies directly with VCs, family offices, and CVCs actively seeking Seed-to-Series B opportunities in life sciences ([LSX Investival Showcase USA](https://informaconnect.com/investival-showcase-usa/)). |
| 11 | Global Corporate Venturing Summit / GCV Symposium | Feb. 23–25, 2027 Monterey; Jun. 23–24, 2026 London | MEDIUM | CVC network mapping; target pharma CVC and enterprise AI CVCs, not public pitch | GCV Summit is positioned as a dedicated gathering of corporate venture capital and C-suite innovation leadership, and GCV Symposium 2026 lists 65% corporate/CVC attendees and 1,500+ meetings ([GCVI Summit](https://www.gcvisummit.com), [GCV Symposium](https://www.gcvsymposium.com)). |
| 12 | StartUp Health Apollo House at JPM Week | Jan. 2027 likely TBA; 2026 was Jan. 13 in San Francisco | MEDIUM | Request invite / join network; use curated founder-funder introductions | The former StartUp Health Festival has reappeared as Apollo House, an invite-only JPM-week founders-and-funders summit with 500 curated founders, investors, and industry leaders; 2026 was co-hosted with SVB, J&J, Advocate Health, and AWS ([StartUp Health Apollo House](https://www.startuphealth.com/startup-health-blog/startup-health-returns-to-jpm-healthcare-week-with-apollo-house)). |

## Direct answers to the six explicit questions

**BIO Investor Forum 2026:** No separate October/November 2026 BIO Investor Forum was verified; BIO’s own FAQ says that, launching in 2026, BIO focused investor engagement through the BIO Investment & Growth Summit rather than hosting the BIO CEO & Investor Conference and BIO Investor Forum ([BIO BIG FAQ](https://bigs.bio.org/faqs-1/big-summit-same-ceo-investor-conference-bio-investor-forum)). BIO Investor Forum is conceptually distinct from BIO Partnering @JPM Week and BIO International Convention because BIO describes it as an investor conference for early and established private companies and emerging public companies with company presentations and BIO One-on-One Partnering, while BIO’s event list separately includes BIO Partnering @JPM Week and BIO International Convention ([BIO Investor Forum](https://www.bio.org/calendar/bio-investor-forum), [BIO Events](https://www.bio.org/events)). For Verixa, the actionable replacement is BIO BIG 2027 in Miami on Feb. 16–18, 2027, because BIO says it includes business/regulatory sessions, company presentations, BIO Partnering, and networking for investment and BD&L opportunities ([BIO Events](https://www.bio.org/events)).

**HLTH 2026:** Yes, HLTH USA 2026 has a dedicated startup pitch competition that is useful for a seed-stage health AI company, because finalists pitch on the HLTH Main Stage and applications are reviewed on a rolling basis until finalist spots are filled ([HLTH Startup Pitch Application](https://hlth.com/events/usa/startup-pitch-application/)). The pitch competition is especially strong for Verixa because HLTH lists prior judges including a16z, GV, Khosla Ventures, General Catalyst, Flare Capital, Cigna Ventures, Cleveland Clinic, Oak HC/FT, McKesson Ventures, Mount Sinai, and SamsungNEXT ([HLTH Startup Pitch](https://hlth.com/events/usa/agenda/startup-pitch/)).

**Slush 2026:** Slush 2026 is relevant for an India-based seed founder pitching pharma AI if Verixa is framed as regulated AI/deeptech enterprise SaaS rather than as a narrow pharma-services vendor, because Slush hosts 5,800 startups and 3,300 investors and offers a meeting area, investor office hours, mentoring, and founder side events ([Slush FAQ](https://slush.org/faq), [Slush](https://slush.org)). Slush is less targeted than BIO/LSX/RESI for pharma-specific capital, so Verixa should pre-book investor meetings with AI, B2B SaaS, deeptech, and digital health funds before traveling ([Slush](https://slush.org)).

**Best India-specific pharma/life-sciences investor event not organized by TiE, BTS, or BioAsia:** For pharma strategic and policy access, India Pharma is the strongest specific event found because it is organized by the Department of Pharmaceuticals with FICCI and IPA and brought together policymakers, global industry leaders, researchers, innovators, and finance stakeholders ([PIB announcement](https://www.pib.gov.in/PressReleasePage.aspx?PRID=2246902&reg=6&lang=1), [PIB conclusion note](https://www.pib.gov.in/PressReleasePage.aspx?PRID=2251887&reg=1&lang=1)). For seed-stage pitch and investor access, C-CAMP NBEC is the strongest actionable program because the 2026 startup track offered up to INR 20 crore in prize money and investment opportunities across healthcare, digital health, AI/ML, diagnostics, and biotech ([IIMA Ventures / C-CAMP post](https://www.linkedin.com/posts/iimaventures_iimaventures-ccamp-nbec-activity-7462441875308892160-huS0)).

**EIT Health Innovation Day access for non-EU companies:** EIT Health i-Days is not a good direct route for Verixa because EIT describes i-Days as student-focused programmes held in academic institutions around Europe, with winners attending a student competition event ([EIT Health i-Days](https://eithealth.eu/programmes/i-days/)). EIT Health Innovation Validation is more relevant but not a simple non-EU founder pitch route, because applicants need a consortium of at least two organisations from different countries and a commercialising company lead for digital or AI-enabled medical technologies at Innovation Maturity Level 6 ([EIT Health Innovation Validation](https://eithealth.eu/opportunity/innovation-validation/)).

**LSX World Congress seed-friendliness:** LSX World Congress is seed-friendly rather than late-stage-only, because the official page states that it serves early-stage Seed–Series B biotech, medical device, diagnostics, and digital health companies, including university spin-outs ([LSX World Congress](https://informaconnect.com/lsx-world-congress/)). For Verixa, LSX should be treated as a high-quality 1:1 investor-partnering forum rather than a broad SaaS expo, because its positioning is life-science fundraising and investment with partneringONE meetings ([LSX partneringONE](https://informaconnect.com/lsx-world-congress/partnering/)).

## Detailed event findings

### United States and North America

| Event | Organizer | Date/window | Location | Investor types present | Audience size / funding signal | Why high ROI for Verixa | Posture | Application / deadline | Official URL | ROI tier | Gap filled |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RESI JPM 2027 / RESI San Francisco | Life Science Nation / RESI | Jan. 11–12, 2027 in person; Jan. 13, 18–19 virtual partnering | San Francisco, CA | Early-stage life-science VCs, angels, family offices, strategics, licensing partners | Prior RESI JPM drew 1,000+ attendees and 500+ early-stage life-science investors | Best SF/JPM-week investor density beyond the already tracked JPM/BIO Partnering/Biotech Showcase; Verixa can pitch privately under NDA before public clearance | 1:1 partnering first; company presentation only after patent/compliance clearance | Partnering typically opens before event; 2026 page says partnering launched Nov. 24 | [RESI JPM](https://www.resiconference.com/resi-jpm/) | HIGH | Adds missing RESI SF/JPM edition |
| BIO Investment & Growth Summit 2027 | BIO | Feb. 16–18, 2027 | Miami, FL | Biotech CEOs, investors, investment banking, BD&L, strategic partners | 2026 BIG page cited 400+ investors, biotech innovators, and biopharma executives | Relevant for pharma strategic capital and regulatory/BD framing, but less perfect for SaaS unless positioned as pharma QMS infrastructure | Partnering + company presentation | 2027 details on BIO events list; monitor BIO partnering access | [BIO Events](https://www.bio.org/events), [BIO BIG](https://bigs.bio.org/about) | MEDIUM-HIGH | Corrects BIO Investor Forum 2026 gap |
| FT US Pharma & Biotech Summit with Endpoints News | FT Live + Endpoints News | 2026 was May 14; 2027 TBA | New York City | Biopharma executives, investors, regulators, R&D and technology specialists | 2026 expected 350+ attendees, 30 speakers, 200 companies, and 50 countries | Strong for pharma AI/regulatory narrative and strategic credibility; weak for formal seed pitching | Attend/network; pursue sponsor/introduction routes | 2027 not posted in verified sources | [FT US Pharma & Biotech Summit](https://uspharma2026.live.ft.com) | MEDIUM | Adds Endpoints/FT investor-policy forum |
| Endpoints “Top 100 Venture Investors in Biotech” webinar | Endpoints News + DealForma | 2026 webinar listed Feb. 26 and event page lists investor webinar series | Virtual | Top biotech VC analysts and partners | Webinar format; no direct pitch slot found | Useful for investor mapping, not primary fundraising | Listen, map investors, request warm intros | No startup application found | [Endpoints Events](https://endpoints.studio/events/), [Forbion event note](https://forbion.com/news-insights/events/endpoints-events-2026-the-top-100-venture-investors-in-biotech/) | SPECULATIVE | Clarifies Endpoints Summit alternative |
| Rock Health Summit 2026 | Rock Health | Oct. 14, 2026 | San Francisco, CA | Digital health VCs, entrepreneurs, payers, providers, health systems, consultants | Rock Health Summit describes an ecosystem convening; external listing cites around 1,000 ecosystem leaders | Excellent digital health investor credibility and AI-in-health narrative, but no formal pitch track found | Attend with pre-booked investor meetings | Registration open; no startup pitch deadline found | [Rock Health Summit](https://www.rockhealthsummit.com) | HIGH | Adds digital-health VC summit |
| HLTH USA Startup Pitch 2026 | HLTH | Nov. 15–18, 2026; finale Nov. 18 | Las Vegas, NV | Healthcare VCs, CVCs, strategics, operators, decision-makers | 12,250+ attendees; prior judges include a16z, GV, Khosla, General Catalyst, Flare, Cigna Ventures, Cleveland Clinic, Oak HC/FT, McKesson Ventures, Mount Sinai, SamsungNEXT | Best broad US healthcare AI startup stage; can target AI, pharma, payer/provider, and enterprise buyers | Apply to pitch after clearance; otherwise use 1:1 networking | Rolling applications until finalist spots filled | [HLTH USA](https://hlth.com/events/usa/), [HLTH Startup Pitch](https://hlth.com/events/usa/agenda/startup-pitch/) | HIGH | Adds major health AI pitch stage |
| MedCity INVEST / Pitch Perfect | MedCity News | 2026/2027 next cycle TBA; 2025 was May 20–21 in Chicago | Chicago, IL | Healthcare investors judging biopharma, devices/diagnostics, payer/provider healthtech, consumer/employer healthtech | 2025 Pitch Perfect had four tracks and a $20,000 branding package for winners | Fit if Verixa enters payer/provider or biopharma AI track; less pharma-QMS-specific than RESI/LSX | Pitch competition if public clearance available | Prior cycle deadline was Jan. 24, 2025; monitor 2027 | [MedCity INVEST Pitch Perfect](https://medcitynews.com/2025/01/healthcare-startups-are-running-out-of-time/) | MEDIUM | Adds MedCity investor pitch route |
| MedCity Bullseye | MedCity News | Jul. 23, 2026 | Chicago, IL | Institutional healthcare investors and corporate BD leads | Invitation-only and exclusively for healthcare investors and corporate business development leads | Useful only through investor-side referrals; founders are not the intended attendee type | Do not prioritize as founder event; use for referral targeting | Waitlist for qualified investors/BD, not founders | [MedCity Bullseye](https://medcitynews.com/2026/05/inviting-investors-and-corporate-business-development-leaders-to-bullseye/) | SPECULATIVE | Clarifies MedCity investor-only forum |
| DHNY Summit | Digital Health New York | Sep. 17, 2026 | New York City | Entrepreneurs, investors, payers, providers, executives, policy leaders | Invitation-only gathering of New York digital health leaders | Good investor/operator credibility for AI deployment and regulated health workflows, but invite-only | Request invite via NY digital health network; 1:1 posture | No public pitch application found | [DHNY Summit](https://www.dhnysummit.com/home), [DHNY Investment Trends](https://www.dhny.co/2026-hcvc-exec-summary) | MEDIUM | Adds NY digital health VC network |
| Fierce JPM Week Breakfast / Fierce JPM Week | Fierce | 2026 was Jan. 13–14; 2027 TBA | San Francisco, CA | Biopharma executives, dealmakers, investors, BD | 2026 registration page showed content, networking, breakfast, lunch, cocktail reception, and meeting/working space | Useful JPM-week side event but not a founder pitch competition | Attend only if already in SF for JPM/RESI; use meetings | 2027 TBA | [Fierce JPM Week registration](https://showpro.cdsreg.com/EventRegistration/FJPM0126/Register/New/step/7c110e10-64ac-4870-9c95-bf128b1f4f27?regId=a34d4af6-6d33-48d7-a1cf-b7d6abec0c41&flowId=d0920c0a-9d5b-4f85-8477-6568dcb5d763), [Fierce session page](https://www.fiercejpmweek.com/event/jpmorgan-breakfast-2026/session/registration-0) | SPECULATIVE | Clarifies founder accessibility |
| StartUp Health Apollo House | StartUp Health | 2026 was Jan. 13; 2027 TBA | San Francisco, CA | Founders, funders, health systems, big tech, health leaders | 2026 Apollo House was positioned as an invite-only 500-person JPM-week summit | Useful for curated digital health founder-funder access; membership/network gated | Request invite; join StartUp Health Network if strategic | 2027 TBA | [StartUp Health Apollo House](https://www.startuphealth.com/startup-health-blog/startup-health-returns-to-jpm-healthcare-week-with-apollo-house) | MEDIUM | Replaces old StartUp Health Festival tracking |
| MATTER Chicago programs | MATTER | Rolling programs/events; specific 2026 summit not strongly verified | Chicago, IL | Healthcare innovators, entrepreneurs, industry executives, investors | MATTER says it equips entrepreneurs with an expansive network and brings together industry executives, entrepreneurs, and investors | Good ecosystem channel for US healthcare pilots; weaker as seed investor event | Program/community route; not a single event priority | Monitor MATTER programs and accelerators | [MATTER](https://matter.health), [MATTER startups](https://www.matter.health/startups) | MEDIUM | Adds Chicago healthcare innovation network |
| Axios Future of Health Summit | Axios | 2026 was May 13 | Washington, DC / virtual | Policy, healthcare executives, innovators | Public summit; no pitch track found | Good for policy/regulatory context, not fundraising | Watch only; do not spend travel budget | No startup application found | [Axios Future of Health coverage](https://www.axios.com/2026/05/15/axios-future-of-health-summit-us-health-care-prices-are-unsustainable-leaders-agree) | SPECULATIVE | Clarifies low fundraising ROI |
| Digital Healthcare Innovation Summit East + Cooley Capital Call | DHIS + Cooley | 2026 was Apr. 27–28; 2027 TBA | Boston, MA | Digital health VCs, payers, providers, policymakers, industry leaders | Cooley Capital Call targeted seed-to-Series A digital health companies and DHIS convenes investors, startups, payers, providers, and policymakers | High fit for AI healthcare workflow and pharma IT/services; public forum risk must be managed | Apply when next Capital Call opens | 2026 deadline was Feb. 27 | [Cooley Capital Call](https://www.cooley.com/events/2026/2026-04-27-call-for-applications-cooley-capital-call-at-digital-healthcare-innovation-summit), [DHIS East](https://dhis.net/east) | HIGH | Adds digital health seed pitch route |

### Europe and UK

| Event | Organizer | Date/window | Location | Investor types present | Audience size / funding signal | Why high ROI for Verixa | Posture | Application / deadline | Official URL | ROI tier | Gap filled |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LSX World Congress Europe 2027 | Informa Connect / LSX | Apr. 6 pre-day; Apr. 7–8 main days | Lyon, France | Life-science VCs, strategics, CVCs, BD partners | Official page says early-stage Seed–Series B companies are in scope | Strongest EU investor-partnering gap after BIO-Europe; good for EU AI/GMP compliance narrative | 1:1 partnering and investor pitch | Registration/partnering approval required | [LSX World Congress](https://informaconnect.com/lsx-world-congress/), [LSX partneringONE](https://informaconnect.com/lsx-world-congress/partnering/) | HIGH | Adds EU fundraising and partnering event |
| Frontiers Health 2026 | Frontiers Health | Oct. 20–21, 2026 | Berlin, Germany | Digital health VCs, entrepreneurs, healthcare transformation leaders | Official page positions event around digital therapies, breakthrough technologies, investments, and ecosystem development | Strong EU digital health / regulated AI venue; less pure pharma-QMS than LSX | Attend and seek pitch/networking opportunities; confirm startup track | Startup/pitch details not verified | [Frontiers Health](https://www.frontiers.health) | MEDIUM-HIGH | Adds EU digital health investor summit |
| Slush 2026 | Slush / Startup Foundation | Nov. 18–19, 2026 | Helsinki, Finland | Global seed VCs, growth funds, angels, tech media, ecosystem partners | 5,800 startups, 3,300 investors, 2,100 partners/ecosystem builders | High investor density for seed; Verixa should frame as regulated AI infrastructure for life sciences | Meeting tool, investor office hours, side events | Startup ticket and pre-registration open | [Slush](https://slush.org), [Slush FAQ](https://slush.org/faq) | HIGH | Adds Nordic/global VC route |
| VivaTech Startup Challenges | Viva Technology | 2026 was Jun. 17–20; 2027 likely Jun. TBA | Paris, France | Corporate innovation teams, investors, large enterprises, tech leaders | CCI Paris noted 14,000 startups and 3,600 investors expected in 2026 | Useful for enterprise AI and corporate partnerships; less targeted to pharma investors unless a pharma/AI challenge exists | Apply to Startup Challenges after clearance | 2026 Next Startupper Award applications closed Mar. 9 | [VivaTech challenge terms](https://challenges.vivatech.com/en/challenges/next-startupper-award/agreements?lang=en), [CCI Paris VivaTech](https://www.cci-paris-idf.fr/fr/entreprises/actualites/vivatech-evenement-startups-innovation) | MEDIUM | Adds broad EU tech VC/corporate event |
| EU-Startups Summit 2027 | EU-Startups | May 13–14, 2027 | Malta | Seed investors and European startup ecosystem | 2026 summit pitch competition selected 15 early-stage startups from 1,500+ applications and offered a prize package worth €755k; 2027 Eventbrite page cites prize package up to €1m | Relevant for seed SaaS visibility; weak pharma specificity | Apply for pitch if public clearance ready | 2027 application details TBA | [EU-Startups Summit 2026](https://www.eu-startups.com/summit/), [EU-Startups Summit 2027 Eventbrite](https://www.eventbrite.co.uk/e/eu-startups-summit-tickets-1989206057867) | MEDIUM | Adds EU seed pitch competition |
| HealthTech Investor Summit 2026 | HealthTech Investor Summit / BioAlps partners | Nov. 30–Dec. 2, 2026 | Bruges, Belgium | 100+ life-science and healthtech investors | Official BioAlps page says companies can pitch to 100+ life-science investors | High fit for EU healthtech investor access, but European-company eligibility should be confirmed | Apply to pitch; budget for pitch fee | 2026 application deadline was Jun. 15; selected projects pay fees | [BioAlps HIS application](https://bioalps.org/healthtech-investor-summit-application-to-pitch/), [HIS pitch page](https://www.healthtechinvestorsummit.com/pitch/) | MEDIUM-HIGH | Adds dedicated healthtech investor summit |
| EIT Health i-Days / Innovation Validation / Jumpstarter | EIT Health | 2026 calls and i-Days | Europe | EU health innovation ecosystem, mentors, funding bodies | Innovation Validation funds up to 50% of project budgets up to €800,000 for selected projects | Potential EU partner route but not a direct non-EU seed pitch event | Use only through EU partner/consortium | Innovation Validation 2026 window listed Feb. 25–May 6 | [EIT i-Days](https://eithealth.eu/programmes/i-days/), [EIT Innovation Validation](https://eithealth.eu/opportunity/innovation-validation/), [EIT Jumpstarter](https://eithealth.eu/news-article/eit-jumpstarter-2026/) | SPECULATIVE | Clarifies non-EU accessibility |
| LSX Investival Showcase Europe | Informa Connect / LSX | Nov. 16, 2026 | London, UK | Life-science and healthcare executives, capital providers, partners | Official page cites 1,000+ attendees and 400+ investors/strategics | Strong investor access for life-science healthcare companies, but 2026 proximity to BIO-Europe may create travel conflict | 1:1 partnering and investor meetings | Registration/partnering | [LSX Investival Showcase Europe](https://informaconnect.com/investival-showcase/) | MEDIUM-HIGH | Adds London life-science capital event |
| GCV Symposium 2026 | Global Corporate Venturing | Jun. 23–24, 2026 | London, UK | Corporate VCs, corporate innovation leaders, VCs | Official page lists 300+ delegates, 1,500+ meetings, and 65% corporate/CVC attendance | Good for pharma CVC and enterprise AI CVC mapping; not health-specific | CVC networking | Registration; founder access should be verified | [GCV Symposium](https://www.gcvsymposium.com) | MEDIUM | Adds CVC network |
| biocap | Messe Berlin | Jun. 9–11, 2026 | Berlin, Germany | Pharma companies, life-science AI startups, VCs, CVCs, angels, government/funding bodies | Messe Berlin positions biocap as a life-science and AI investival with matchmaking, 1:1 meetings, and a pitch stage | Very relevant thematic fit for AI + pharma, but 2026 timing has passed and track record is new | Monitor 2027 if repeated | 2027 not found | [Messe Berlin biocap](https://www.messe-berlin.de/en/biocap.html) | MEDIUM | Adds AI-pharma investival |
| Pioneers Festival | Pioneers | No current 2026/2027 official event verified | Vienna historically | Startup investors and future-tech founders historically | Search results were largely historical | Do not prioritize until current edition is verified | None | No current official page verified | [Pioneers](https://www.pioneers.io) | SPECULATIVE | Avoids stale recommendation |
| HolonIQ World Health Innovation Summit | HolonIQ / QS ecosystem | No credible 2026/2027 investor summit page verified | Not verified | Healthtech data/research ecosystem | Search found HolonIQ healthtech rankings, not a clear event | Not actionable as fundraising event | Monitor only | [HolonIQ Health Tech 200 note](https://www.holoniq.com/notes/2022-europe-health-tech-200) | SPECULATIVE | Avoids unclear event |

### India

| Event | Organizer | Date/window | Location | Investor types present | Audience size / funding signal | Why high ROI for Verixa | Posture | Application / deadline | Official URL | ROI tier | Gap filled |
|---|---|---|---|---|---|---|---|---|---|---|---|
| India Pharma Conference | Department of Pharmaceuticals + FICCI + Indian Pharmaceutical Alliance | 2026 was Apr. 13–14; next cycle TBA | New Delhi | Pharma leadership, policymakers, finance stakeholders, industry, academia, investors | 2026 had 800+ delegates, 60+ speakers, 10 sessions, and a financing plenary on VC/PE/blended finance/PPP | Best India pharma strategic event outside TiE/BTS/BioAsia; directly relevant to Schedule M, GMP, pharma innovation, and compliance | Strategic investor/CVC meetings; policy-networking | 2027 TBA | [PIB announcement](https://www.pib.gov.in/PressReleasePage.aspx?PRID=2246902&reg=6&lang=1), [PIB conclusion note](https://www.pib.gov.in/PressReleasePage.aspx?PRID=2251887&reg=1&lang=1) | HIGH | Adds India pharma financing/policy forum |
| C-CAMP National Bio Entrepreneurship Competition (NBEC) | C-CAMP, with partners including IIMA Ventures | 2026 applications closed Jun. 15; next cycle likely 2027 | India / program-based | Bio/life-science investors, incubators, grant and prize partners | 2026 offered up to INR 20 crore in cash prizes and investment opportunities for startup/innovator track | Best seed-stage Indian life-science pitch credential; includes digital health and AI/ML scope | Apply next cycle; pitch after clearance | 2026 deadline Jun. 15, 5:30 PM IST | [IIMA Ventures / C-CAMP post](https://www.linkedin.com/posts/iimaventures_iimaventures-ccamp-nbec-activity-7462441875308892160-huS0), [IndiaBioscience post](https://x.com/IndiaBioscience/status/2059185766283243568) | HIGH | Adds India biotech startup competition |
| Global Bio-India | BIRAC / DBT | 2024 program verified; next cycle TBA | New Delhi historically | Biotech industry, investors, startups, regulators, technology-transfer stakeholders | Program included startup pitches and an IVCA-powered investor roundtable | Strong if next edition is announced; more biotech/bioeconomy than pure SaaS | Startup pitch + investor roundtable | Next cycle not verified | [Global Bio-India program](https://globalbioindia.org/program) | MEDIUM-HIGH | Adds national biotech-investor platform |
| NASSCOM Product Conclave | NASSCOM | 2026/2027 cycle TBA | India | SaaS/product investors, enterprise buyers, founders | Search result says NPC is attended by around 2,000 Indian product ecosystem participants | Good for SaaS investor access but not pharma/life-science-specific | Attend only if India SaaS fundraising is primary | 2026/2027 details not verified due site access limits | [NASSCOM Product Conclave](https://productconclave.nasscom.in) | MEDIUM | Adds India SaaS investor route |
| LHIF_15 Healthcare AI Startup Showcase | NASSCOM-linked LHIF listing found | Jun. 3, 2026 | Bengaluru | Hospital decision-makers, pharma enterprises, healthcare investors | LinkedIn event post described investor and pharma/hospital decision-maker access | Very relevant to India healthcare AI, but 2026 has passed and official page was not fetched | Monitor next LHIF/showcase | 2026 contact was lhif@nasscom.in | [LHIF_15 post](https://www.linkedin.com/posts/mittalsudhanshu00_deeptechstartups-lhif15-activity-7460266521915858944-_47F) | MEDIUM | Adds healthcare AI showcase |
| T-Hub AIC Healthcare Program | AIC T-Hub | 2026 cohort timeline listed demo day Mar. 30 | Hyderabad | Mentors, investors, healthcare experts, service providers | Program supports MVP-stage startups with commercialization access to global mentors, investors, industry experts, and demo day | Useful because Hyderabad is pharma/life-sciences dense and Verixa is India-based | Program/demo day | 2026 closure Feb. 28; next cohort TBA | [T-Hub Healthcare Program](https://t-hub.co/healthcare) | MEDIUM-HIGH | Adds Hyderabad healthcare accelerator |
| T-Hub / Eli Lilly Solution Accelerator | T-Hub + Eli Lilly | 2026 cohort referenced | Hyderabad / hybrid | Pharma corporate innovation, Lilly experts, startup ecosystem | T-Hub/Lilly post described tech-driven healthcare and pharma startups receiving technical guidance from Lilly experts | Direct pharma strategic route if new cohorts open for AI/SLM/pharma workflows | Corporate challenge / pilot-first | 2026 launch passed; monitor new cohorts | [T-Hub Lilly Accelerator post](https://www.linkedin.com/posts/thubhyd_lilly-solution-accelerator-program-launch-activity-7313492982786068480-e0WL) | MEDIUM-HIGH | Adds pharma corporate innovation route |
| Life Sciences Commercial Summit | Independent / T-Hub-hosted | Jun. 4, 2026 | Hyderabad | Life-science GCC/commercial AI leaders, pharma technology leaders | Event focused on life-science GCCs, AI strategy, CRM, data systems, and measurable commercial AI return | Relevant for pharma AI enterprise buyers, but not investor-first | Strategic pilot networking | 2026 passed | [Life Sciences Commercial Summit](https://www.lifesciencescommercialsummit.com) | MEDIUM | Adds pharma AI commercial network |
| Healthcare Summit Apex Startup Arena | Healthcare Summit | Jun. 12–13, 2026 | Hyderabad | Pharma leaders, hospital CXOs, investors, global healthcare stakeholders | Startup Arena is described as a curated DeepTech & AI showcase for collaboration, pilots, and investments | Strong India healthcare AI showcase; confirm pharma-QMS relevance with organizer before applying | Startup showcase | 2026 passed; monitor 2027 | [Apex Startup Arena](https://healthcaresummit.in/apex-start-up-arena/) | MEDIUM | Adds India health AI showcase |
| Pharmexcil / FTCCI pharma investor roundtable | Pharmexcil circular / FTCCI / Invest UP | Jan. 5, 2026 | Hyderabad | Pharma companies, UP government/investment officials | Pharmexcil circulated a focused investor roundtable for pharma members | Not startup-pitch oriented but useful for pharma policy/manufacturing networks | Watch Pharmexcil circulars; attend member roundtables | Event passed | [Pharmexcil circular](https://pharmexcil.com/circulars/viewcirculars/14219/94dfab955da4b95dc242a39aa3ddb104.html) | SPECULATIVE | Confirms Pharmexcil investor meets exist, but not startup-specific |
| iPHEX 2026 | Pharmexcil + Department of Commerce | Sep. 7–9, 2026 | Bharat Mandapam, New Delhi | Pharma exporters, global buyers, industry delegates | Embassy notice says iPHEX brings together 900+ Indian exhibitors and delegates from 50+ countries | Good pharma-buyer ecosystem but weak seed fundraising fit for SaaS | Strategic customer discovery, not investor pitch | Exhibition participation route | [iPHEX notice PDF](https://www.indembassyuae.gov.in/content/Notice-iPHEX-2026.pdf) | SPECULATIVE | Adds pharma trade forum, not investor event |
| Startup India Showcase | Startup India | Ongoing platform | Online / India | Government-recognized startup discovery ecosystem | Official page fetch failed; no healthcare/pharma AI investor event verified | Useful as credibility listing but not an event | Profile/listing only | [Startup India Showcase](https://www.startupindia.gov.in/content/sih/en/showcase.html) | SPECULATIVE | Clarifies it is not a specific investor event |
| NSRCEL Healthcare Incubation Program / MedTech Day | NSRCEL IIM Bangalore + DailyRounds | 2026 MedTech Day happened; next TBA | Bengaluru | Investors, clinicians, ecosystem leaders, healthcare innovators | MedTech Day event page says it brought innovators, investors, clinicians, and ecosystem leaders together | Good local healthcare validation and investor access; not pharma-QMS-specific | Program/demo day | Next cohort TBA | [NSRCEL Healthcare Program](https://nsrcel.org/healthcare-incubation-program), [MedTech Day 2026](https://luma.com/2eynykxw) | MEDIUM | Adds IIM Bangalore healthcare route |
| IIMA Ventures Summit / Healthcare legacy | IIMA Ventures | 2026 summit happened; next TBA | Ahmedabad | Founders, investors, policymakers, alumni | IIMA Ventures post says summit had 1,000+ attendees and 40+ startup exhibits | Relevant India investor access, especially via IIMA Ventures/NBEC connection | Network/demo | Next cycle TBA | [IIMA Ventures post](https://www.linkedin.com/posts/iimaventures_iimaventures-nationstartupday-iimaventuressummit2026-activity-7417860017535754240-ZBd2), [IIMA Ventures](https://iimaventures.com) | MEDIUM | Adds IIM Ahmedabad route |
| Cipla Innoventia | Cipla | Historical; no 2026 active cycle verified | India | Cipla innovation/corporate investment | Moneycontrol reported Cipla’s Innoventia challenge could invest from a few crore rupees up to $15 million | Useful historical signal of pharma corporate openness, but no current cycle found | Monitor Cipla corporate innovation; do not count as current event | No current 2026 deadline found | [Moneycontrol Cipla Innoventia](https://www.moneycontrol.com/news/business/companies/cipla-goes-beyond-pill-keen-on-investing-in-innovations-in-patient-care-drug-delivery-technologies-4532591.html) | SPECULATIVE | Clarifies corporate challenge status |
| Sun Pharma / Dr. Reddy’s innovation challenges | Sun Pharma / Dr. Reddy’s | No current pitch challenge verified | India | Pharma corporate innovation | Search did not verify a 2026 startup challenge comparable to Cipla Innoventia | Track as strategic outreach targets, not events | Direct BD/outreach | No current deadline found | [Dr. Reddy’s digital push](https://cio.economictimes.indiatimes.com/news/strategy-and-management/dr-reddys-gears-up-for-a-massive-digital-push/91953568) | SPECULATIVE | Avoids unsupported event recommendation |
| India Health Fund | Tata Trusts + Global Fund initiative | Ongoing support model | India | Grant/impact funding, health innovation partners | IHF supports technology and science-led innovations with development, validation, regulatory, and adoption support | More diagnostics/public-health oriented than pharma-QMS; useful only if Verixa maps to quality/access impact | Funding/support application, not investor event | Check rolling support criteria | [India Health Fund support](https://www.indiahealthfund.org/our-support/) | SPECULATIVE | Clarifies program vs investor event |

### Accelerators and programs

| Program | Organizer | Date/window | Location | Investor types present | Audience size / funding signal | Why ROI for Verixa | Posture | Application / deadline | Official URL | ROI tier | Gap filled |
|---|---|---|---|---|---|---|---|---|---|---|---|
| HAX | SOSV / HAX | Rolling | Newark, NJ and global | SOSV hardtech venture network, follow-on investors | HAX says it backs pre-seed startups at the intersection of science and engineering, including health tech, advanced compute, physical AI, and manufacturing | Verixa is software-heavy, so fit depends on positioning as regulated AI infrastructure for manufacturing/QMS rather than pure SaaS | Apply only if HAX confirms software/AI QMS fit | Rolling / source-dependent | [HAX](https://hax.co) | SPECULATIVE-MEDIUM | Adds deeptech accelerator check |
| J&J JLABS Investor & Partnering Day | Johnson & Johnson Innovation / JLABS | 2025/2026 cycle TBA; 2024 example was May 2 in NYC | NYC / JLABS network | Life-science investors, JJDC, J&J Innovation, biotech CEOs | 2024 page targeted pre-seed, seed, and Series A startups seeking funding in the next 12–18 months and offered matched 1:1 investor meetings | Strong pharma strategic credibility; Verixa needs to confirm software/pharma-QMS eligibility | Apply if 2026/2027 call opens; private 1:1 posture | 2024 deadline was Mar. 22 | [JLABS Investor & Partnering Day](https://innovation.weill.cornell.edu/events/jlabs-investor-partnering-day-application%E2%80%AFdeadline-32224), [JLABS](https://www.jnj-jlabs.com) | MEDIUM-HIGH | Adds pharma CVC/partnering program |
| MATTER programs / Paratus digital health accelerator | MATTER / BARDA Accelerator Network | Rolling | Chicago / virtual | Healthcare innovation mentors, entrepreneurs, industry, investors | MATTER describes entrepreneur support, investor/community access, and Paratus digital health opportunities | Relevant if Verixa ties QMS AI to public-health preparedness, pharma quality, or regulated health infrastructure | Program route | Monitor Paratus and MATTER startup opportunities | [MATTER startups](https://www.matter.health/startups) | MEDIUM | Adds US health accelerator |
| BIRAC BIG | BIRAC | Rolling registration; calls by cycle | India | Non-dilutive grant ecosystem, incubators | BIG provides grant-in-aid up to INR 50 lakhs for 18 months for Indian entrepreneurs and startups | Good non-dilutive validation if patent/PoC and biotech/digital health fit are acceptable | Grant application; not investor event | Register under BIRAC BIG user; current cycle details need portal check | [BIRAC BIG call](https://birac.nic.in/cfp_view.php?id=30&scheme_type=5), [myScheme BIG](https://www.myscheme.gov.in/schemes/big&rut=efc299661a1663cdb424adb13eadcfa4f67ec1c4ce94c2a3a02c709290a7b441) | MEDIUM-HIGH | Adds India non-dilutive life-science route |
| Villgro | Villgro | Rolling / calls vary | Bengaluru and global | Impact investors, incubation partners, healthcare ecosystem | Villgro lists healthcare as a focus sector and invites innovators to apply for incubation | Useful if Verixa can make access/quality impact case; less aligned with pharma enterprise SaaS fundraising | Incubation application | Rolling / call-specific | [Villgro](https://villgro.org) | MEDIUM | Adds India impact-health route |
| NSRCEL Healthcare Incubation | NSRCEL IIM Bangalore + DailyRounds | Cohort-based | Bengaluru | Healthcare mentors, investors, clinicians, ecosystem leaders | Program supports early-stage healthcare startups from ideation to proof-of-concept | Good for local validation and healthcare investor introductions; less pharma-specific | Program/demo day | Cohort TBA | [NSRCEL Healthcare Program](https://nsrcel.org/healthcare-incubation-program) | MEDIUM | Adds healthcare incubator route |
| IIMA Ventures | IIMA Ventures | Cohort/summit-based | Ahmedabad | Investors, policymakers, founders, alumni | IIMA Ventures is linked to NBEC as investment partner and hosted a 1,000+ attendee summit | Useful for India deeptech/healthcare investor validation | Network and program route | TBA | [IIMA Ventures](https://iimaventures.com), [IIMA Ventures NBEC](https://www.linkedin.com/posts/iimaventures_iimaventures-ccamp-nbec-activity-7462441875308892160-huS0) | MEDIUM | Adds IIM Ahmedabad channel |

### Global / online and CVC access

| Event / channel | Organizer | Date/window | Location | Investor types present | Audience size / funding signal | Why ROI for Verixa | Posture | Application / deadline | Official URL | ROI tier | Gap filled |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Biotechgate Digital Partnering | Biotechgate / Venture Valuation ecosystem | Feb. 23–27, 2026 and Aug. 31–Sep. 4, 2026 listed | Virtual | Pharma, biotech, medtech, digital health, corporate investors | Swiss Biotech says the event hosts 1,000+ representatives from leading life-science companies and investors and is free to attend | Efficient low-cost way to test global pharma/digital health investor messaging under controlled 1:1 conditions | Partnering-only; avoid public pitch until clearance | Register for next virtual edition | [Swiss Biotech Biotechgate](https://www.swissbiotech.org/event/biotechgate-digital-partnering-february-2026/), [HelloPartnering listing](https://www.hellopartnering.com/login/select/all) | MEDIUM-HIGH | Adds virtual partnering beyond BIO/RESI |
| LifeSci Partners Corporate Access Event | LifeSci Partners | JPM week; 2026 was Jan. 12–13 | San Francisco, CA | Institutional investors, life-science corporates, LifeSci-covered companies | Public company press releases describe investor meetings at LifeSci’s JPM-week corporate access event | Likely less accessible for seed SaaS unless through advisor/introduction | Use only via LifeSci or investor intro | Invite/relationship-based | [StockTitan note](https://www.stocktitan.net/news/CMPX/compass-therapeutics-to-participate-in-the-j-p-morgan-2026-371wikyynyd5.html) | SPECULATIVE | Clarifies corporate-access event |
| Republic / AngelList pharma-tech syndicates | Republic / AngelList | Ongoing | Online | Angels, syndicates, retail/accredited investors | No credible pharma-QMS-specific event was verified | Not recommended before patent/compliance clearance because public fundraising materials create disclosure risk | Defer until IP and compliance clearance | Platform-specific | [AngelList](https://www.angellist.com), [Republic](https://republic.com) | SPECULATIVE | Clarifies online syndicate risk |
| Global Corporate Venturing Summit | GCV | Feb. 23–25, 2027 | Monterey, CA | Corporate venture capital, C-suite innovation, VCs | GCV Summit positions itself as the largest dedicated gathering of corporate venture capital and C-suite innovation leadership | Good CVC mapping for Novartis/Roche/J&J/Pfizer-type investors, but founder access must be confirmed | CVC networking / sponsorship route | Registration when open | [GCVI Summit](https://www.gcvisummit.com) | MEDIUM | Adds global CVC network |
| Pharma Investment World / generic pharma investment conferences | Various conference organizers | 2026 dates found, but credibility mixed | Amsterdam/Dubai listings | Pharma executives, investors, academics | Search found generic conference-track pages rather than a recognized investor marketplace | Do not prioritize; likely low signal compared with BIO, LSX, RESI, India Pharma, and HLTH | Avoid unless invited speaker slot is free | Not recommended | [Generic pharma investment track](https://pharmaceuticalindustry.pharmaceuticalconferences.com/events-list/global-pharma-investment-deal-making) | SPECULATIVE | Avoids weak conference lead |

## Recommended near-term action plan for Verixa

1. **Protect IP/compliance while still fundraising:** use RESI JPM 2027, LSX World Congress 2027, Biotechgate Digital Partnering, and JLABS-style events for private 1:1 NDA-protected pitching until the patent filing and compliance gate are cleared.
2. **Make only one or two public pitch bets before the seed close:** HLTH Startup Pitch and Slush are the best public-stage candidates, but Verixa should use them only if patent counsel and compliance approve public materials.
3. **Prioritize India strategic validation in parallel:** India Pharma, NBEC, T-Hub Healthcare/Lilly, and C-CAMP/BIRAC channels give India-specific credibility that can de-risk conversations with US/EU investors.
4. **Do not over-invest in weak or stale leads:** Pioneers Festival, HolonIQ event, Healthtech Nerds standalone investor events, generic Pharma Investment World pages, and Sun/Dr. Reddy’s pitch challenges were not verified as current high-ROI founder fundraising events.